RT Journal Article
SR Electronic
T1 Proteogenomic integration reveals CXCL10 as a potentially downstream causal mediator for IL-6 signaling on atherosclerosis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.24.23287543
DO 10.1101/2023.03.24.23287543
A1 Prapiadou, Savvina
A1 Živković, Luka
A1 Thorand, Barbara
A1 George, Marc J.
A1 van der Laan, Sander W.
A1 Malik, Rainer
A1 Herder, Christian
A1 Koenig, Wolfgang
A1 Ueland, Thor
A1 Kleveland, Ola
A1 Aukrust, Pal
A1 Gullestad, Lars
A1 Bernhagen, Jürgen
A1 Pasterkamp, Gerard
A1 Peters, Annette
A1 Hingorani, Aroon D.
A1 Rosand, Jonathan
A1 Dichgans, Martin
A1 Anderson, Christopher D.
A1 Georgakis, Marios K.
YR 2023
UL http://medrxiv.org/content/early/2023/03/28/2023.03.24.23287543.abstract
AB Background Genetic and experimental studies support a causal involvement of interleukin-6 (IL-6) signaling in atheroprogression. While trials targeting IL-6 signaling are underway, any benefits must be balanced against an impaired host immune response. Dissecting the mechanisms that mediate the effects of IL-6 signaling on atherosclerosis could offer insights about novel drug targets with more specific effects.Methods Leveraging data from 522,681 individuals, we constructed a genetic instrument of 26 variants in the gene encoding the IL-6 receptor (IL-6R) that proxied for pharmacological IL-6R inhibition. Using Mendelian randomization (MR), we assessed its effects on 3,281 plasma proteins quantified with an aptamer-based assay in the INTERVAL cohort (n=3,301). Using mediation MR, we explored proteomic mediators of the effects of genetically proxied IL-6 signaling on coronary artery disease (CAD), large artery atherosclerotic stroke (LAAS), and peripheral artery disease (PAD). For significant mediators, we tested associations of their circulating levels with incident cardiovascular events in a population-based study (n=1,704) and explored the histological, transcriptomic, and cellular phenotypes correlated with their expression levels in samples from human atherosclerotic lesions.Results We found significant effects of genetically proxied IL-6 signaling on 70 circulating proteins involved in cytokine production/regulation and immune cell recruitment/differentiation, which correlated with the proteomic effects of pharmacological IL-6R inhibition in a clinical trial. Among the 70 significant proteins, genetically proxied circulating levels of CXCL10 were associated with risk of CAD, LAAS, and PAD with up to 67% of the effects of genetically downregulated IL-6 signaling on these endpoints mediated by decreases in CXCL10. Higher midlife circulating CXCL10 levels were associated with a larger number of cardiovascular events over 20 years, whereas higher CXCL10 expression in human atherosclerotic lesions correlated with a larger lipid core and a transcriptomic profile reflecting immune cell infiltration, adaptive immune system activation, and cytokine signaling.Conclusions Integrating multiomics data, we found a proteomic signature of IL-6 signaling activation and mediators of its effects on cardiovascular disease. Our analyses suggest the interferon-γ-inducible chemokine CXCL10 to be a potentially causal mediator for atherosclerosis in three vascular compartments and as such could serve as a promising drug target for atheroprotection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCDA is supported by NIH R01NS103924, U01NS069673, AHA 18SFRN34250007, AHA-Bugher 21SFRN812095, and the MGH McCance Center for Brain Health for this work. MKG is supported by a Walter-Benjamin fellowship from the German Research Foundation (DFG, GZ: GE 3461/1-1), the FöFoLe program of LMU Munich (Reg.-Nr. 1120), the DFG Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy – ID 390857198), and the Fritz – Thyssen Foundation (Ref. 10.22.2.024MN). The German Diabetes Center is funded by the German Federal Ministry of Health (Berlin, Germany) and the Ministry of Culture and Science of the state North Rhine–Westphalia (Düsseldorf, Germany) and receives additional funding from the German Federal Ministry of Education and Research (BMBF) through the German Center for Diabetes Research (DZD e.V.). JB is supported by DFG project SFB1123/A3 and EXC 2145 SyNergy – ID 390857198. The KORA study was initiated and financed by the Helmholtz Zentrum München – German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research (BMBF) and by the State of Bavaria. Data collection in the KORA study is done in cooperation with the University Hospital of Augsburg.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All studies have received ethical approvals from the respective ethical authorities. All participants who donated samples to deCODE gave informed consent, and the National Bioethics Committee of Iceland approved the study, which was conducted in agreement with conditions issued by the Data Protection Authority of Iceland (VSN_14-015). Personal identities for the participants' data and biological samples were encrypted by a third-party system (Identity Protection System), approved and monitored by the Data Protection Authority. The study protocol of Athero-EXPRESS conforms to the Declaration of Helsinki and was approved by the ethics committee on research on humans of the University Medical Center Utrecht. All participants provided written informed consent. For all KORA studies as well as the MONICA/KORA case-cohort study approval has been obtained from the Ethics Committee of the Bavarian Medical Association (Bayerische Landesärztekammer). All KORA studies have been approved by the Bavarian commissioner for data protection and privacy (Bayerischer Datenschutzbeauftragter). All study participants have provided written consent after being informed about the study. All subjects have the option to restrict their consent to specific procedures, e. g. by denying storage of biosamples. All participants in INTERVAL also gave informed consent before joining the study and the study received approval from the National Research Ethics Service approved this study (11/EE/0538). Finally, the Norwegian tocilizumab NSTEMI trial has received approval from the Regional Committee for Medical and Health Research Ethics of South-Eastern Norway and the Norwegian Medicines Agency, and conducted according to the Declaration of Helsinki. All participants provided written informed consent. The STARNET protocol has been approved from an institutional review committee (Ethics Review Committee on Human Research of the University of Tartu).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesSummary statistics of the genetic analyses from the INTERVAL and deCODE studies are publicly available online at https://ega-archive.org/datasets/EGAD00001004080/files and https://www.decode.com/summarydata/. The genetic instruments used for the main analyses are provided in Supplementary Table S1 and are available from previous publications.1,8 GWAS summary statistics for coronary artery disease and large artery stroke from the CardioGRAMPLUSC4D Consortium and the MEGASTROKE Consortium are available at http://www.cardiogramplusc4d.org/data-downloads/ and https://www.megastroke.org/download.html, respectively. GWAS summary statistics for PAD have been accessed through dbGAP (pha005161.1) with an approved application by JR and CDA for the Veterans Administration (VA) Million Veteran Program (MVP) Summary Results from Omics Studies. Summary statistics from the NSTEMI trial were accessed through contact of the corresponding authors of the study and are available to interested authors through an application and a short research proposal submitted to the study. Data from the MONICA/KORA study are not publicly available because the data are subject to national data protection laws and restrictions were imposed by the ethics committee of the Bavarian Chamber of Physicians to ensure data privacy of the study participants. However, data are available on request to researchers through a project agreement from KORA (http://epi. helmholtz-muenchen.de/kora-gen/). Requests should be sent to kora.passt@helmholtz-muenchen.de and are subject to approval by the KORA board. The datasets from Athero-Express analyzed for the current study are available upon reasonable request and application to Athero-Express Biobank Study through a Data Transfer Agreement due to consent restrictions and local regulations. The gene expression dataset from STARNET was accessed through dbGAP with an approved application by JR and CDA (phs001203.v1.p1). Data for the single-nuclei transcriptomic analyses were accessed through the Single Cell Portal (https://singlecell.broadinstitute.org/single_cell). The YFS is a population-based prospective follow-up study on cardiovascular risk factors in Finland. It has been carried out in all five Finnish university cities with medical schools and their rural surroundings. The first cross-sectional study was conducted in 1980. Altogether 4,320 children and adolescents aged 3, 6, 9, 12, 15 and 18 years were randomly recruited from the population register of these areas to produce a representative subsample of Finnish children. Of these individuals 3,596 (83%) participated in year 1980. Since then, regular follow-up visits have been performed in 1980, 1983, 1986, 2001, 2007, 2011 and 2018/2020. Follow-up using registry data (diagnoses, medications and mortality) have been extended by 2018. The YFS has been approved by the Joint Commission on Ethics of the Turku University and the Turku University Central Hospital and has been conducted according to the guidelines of the Declaration of Helsinki, and informed consent has been obtained from all participants or their parents. https://ega-archive.org/datasets/EGAD00001004080/files http://www.cardiogramplusc4d.org/data-downloads/ https://www.megastroke.org/download.html http://epi.helmholtz-muenchen.de/kora-gen/ https://singlecell.broadinstitute.org/single_cell https://www.decode.com/summarydata/ CABGCoronary artery bypass graftingCADCoronary artery diseaseCANTOSCanakinumab Anti-Inflammatory Thrombosis Outcomes StudyCBSCystathionine Beta-SynthaseCHARGECohorts for heart and aging research in genomic epidemiologyCIConfidence intervalCRPC-eactive proteinCXCL10C-X-C motif chemokine ligand 10CXCR3C-X-C motif chemokine receptor 3EHRElectronic health recordsFDRFalse discovery rateGOGene ontologyHRHazard ratioIFN-γInterferon gammaIL-6Interleukin-6IL-1Interleukin 1IL6-RInterleukin-6 receptor alpha chainIP-10Interferon-γ-induced protein 10)IVWInverse variance weightedLAASLarge artery atherosclerotic strokeLDLinkage disequilibriumMRMendelian randomizationNSTEMInon–ST-segment–elevation MIPADPeripheral artery diseaseSDStandard deviationSEStandard errorsIL6RSoluble IL-6RSLESystemic lupus erythematosusSTARNETStockholm-Tartu atherosclerosis reverse networks engineering taskTNF-αTumor necrosis factor-α